Global Guillain-Barré Syndrome Treatment Market 2019-2023 – Recent Approvals of Novel Immunoglobulins from Regulatory Bodies Are Expected to Propel Growth –

Guillain-Barré Syndrome Treatment Market 2019-2023”
report has
been added to’s offering.

The Guillain-Barré syndrome treatment market is projected to register a
CAGR of more than 5% by 2023.

The trend of strategic alliances to help market grow at a flourishing
rate. Pharmaceutical companies are working together for the development
of medications for the treatment of Guillain-Barré syndrome. These
alliances will enhance the R&D activities of new drugs for the
management of Guillain-Barré syndrome.

Immunoglobulins are the first line treatment of Guillain-Barré syndrome.
The recent approvals of novel immunoglobulins from regulatory bodies are
expected to propel the growth of the global Guillain-Barré syndrome
treatment market during the forecast period.

Currently there is no cure for Guillain-Barré syndrome. The goal of the
available treatments is to provide relief from the symptoms of disease.
Although the intravenous immunoglobin therapy is more convenient and
widely available, it has certain side effects. Hence, some physicians
are strongly inclined toward other available plasma exchange procedures
for the treatment of Guillain-Barré syndrome.

Key Players

  • CSL
  • Grifols
  • Octapharma
  • Shire
  • Kedrion

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Market Landscape

4. Market Sizing

5. Five Forces Analysis

6. Market Segmentation by Product

7. Customer Landscape

8. Geographic Landscape

9. Decision Framework

10. Drivers and Challenges

11. Trends

12. Vendor Landscape

13. Vendor Analysis

For more information about this report visit

Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Central
Nervous System Drugs